Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q2 2022 · 10-Q
Revenue$56.00K$56.00K−55.2% vs Q2 2021 Net Income-$4.34M-$4.34MN/M vs Q2 2021 EPS Diluted-$0.09-$0.09N/M vs Q2 2021 Gross Profit$38,000+46.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,302,000N/M Free Cash Flowderived-$2,334,000N/M Margins · derivedGross margin67.9%+47.1 pt vs Q2 2021
Operating margin-7764.3%−6423.5 pt vs Q2 2021
Net margin-7757.1%−6431.5 pt vs Q2 2021
ended Sep 30, 2021 · filed Oct 29, 2021 · 29 d after period end